Characterization of Human γδ T Lymphocytes Infiltrating Primary Malignant Melanomas

T lymphocytes are often induced naturally in melanoma patients and infiltrate tumors. Given that γδ T cells mediate antigen-specific killing of tumor cells, we studied the representation and the in vitro cytokine production and cytotoxic activity of tumor infiltrating γδ T cells from 74 patients with primary melanoma. We found that γδ T cells represent the major lymphocyte population infiltrating melanoma, and both Vδ1+ and Vδ2+ cells are involved. The majority of melanoma-infiltrating γδ cells showed effector memory and terminally-differentiated phenotypes and, accordingly, polyclonal γδ T cell lines obtained from tumor-infiltrating immune cells produced IFN-γ and TNF-α and were capable of killing melanoma cell lines in vitro. The cytotoxic capability of Vδ2 cell lines was further improved by pre-treatment of tumor target cells with zoledronate. Moreover, higher rate of γδ T cells isolation and percentages of Vδ2 cells correlate with early stage of development of melanoma and absence of metastasis. Altogether, our results suggest that a natural immune response mediated by γδ T lymphocytes may contribute to the immunosurveillance of melanoma.

[1]  G. Ogg,et al.  Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes , 1998, The Journal of experimental medicine.

[2]  Jeffrey Weber,et al.  Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). , 2008, The oncologist.

[3]  Qunyuan Zhang,et al.  Tumor-Infiltrating γδ T Lymphocytes Predict Clinical Outcome in Human Breast Cancer , 2012, The Journal of Immunology.

[4]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[5]  J. Wiesner,et al.  Microbial isoprenoid biosynthesis and human γδ T cell activation , 2003, FEBS letters.

[6]  B. Bloom,et al.  Natural and synthetic non-peptide antigens recognized by human γδ T cells , 1995, Nature.

[7]  L. Picker,et al.  HUMAN LYMPHOCYTES BEARING T CELL RECEPTOR Y / S ARE PHENOTYPICALLY DIVERSE AND EVENLY DISTRIBUTED THROUGHOUT THE LYMPHOID SYSTEM , 2022 .

[8]  G. Sireci,et al.  Partial and Ineffective Activation of Vγ9Vδ2 T Cells by Mycobacterium tuberculosis-Infected Dendritic Cells , 2010, The Journal of Immunology.

[9]  B. Kimmel,et al.  Reduced Expression of the Mevalonate Pathway Enzyme Farnesyl Pyrophosphate Synthase Unveils Recognition of Tumor Cells by Vγ9Vδ2 T Cells1 , 2009, The Journal of Immunology.

[10]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[11]  G. D. de Bock,et al.  The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis , 2011, British Journal of Cancer.

[12]  E. Oldfield,et al.  Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases , 2007, Proceedings of the National Academy of Sciences.

[13]  D. Kabelitz,et al.  Differentiation of Resting Human Peripheral Blood γδ T Cells toward Th1- or Th2-Phenotype , 2001 .

[14]  F. Poccia,et al.  Differentiation of Effector/Memory Vδ2 T Cells and Migratory Routes in Lymph Nodes or Inflammatory Sites , 2003, The Journal of experimental medicine.

[15]  J. Mönkkönen,et al.  High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. , 2011, Cancer research.

[16]  C. Langford,et al.  Distinct Cytokine-Driven Responses of Activated Blood γδ T Cells: Insights into Unconventional T Cell Pleiotropy1 , 2007, The Journal of Immunology.

[17]  Natale Cascinelli,et al.  Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma , 1996, Cancer.

[18]  Marc Bonneville,et al.  Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. , 2005, Immunity.

[19]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Bonneville,et al.  Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. , 1994, Science.

[21]  A. Hayday Gammadelta T cells and the lymphoid stress-surveillance response. , 2009, Immunity.

[22]  Israel Lowy,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Todaro,et al.  In vivo manipulation of Vγ9Vδ2 T cells with zoledronate and low‐dose interleukin‐2 for immunotherapy of advanced breast cancer patients , 2010, Clinical and experimental immunology.

[24]  M. Bonneville,et al.  γδ T cell effector functions: a blend of innate programming and acquired plasticity , 2010, Nature Reviews Immunology.

[25]  M. Rimbert,et al.  Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma , 2008, Cancer Immunology, Immunotherapy.

[26]  Lisa M. Ebert,et al.  Homing and Function of Human Skin γδ T Cells and NK Cells: Relevance for Tumor Surveillance , 2006, The Journal of Immunology.

[27]  M. Mihm,et al.  Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. , 2010, American journal of clinical pathology.

[28]  G. Sireci,et al.  Differential activation of human γ δ cells by nonpeptide phosphoantigens , 2001, European journal of immunology.

[29]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Lambert,et al.  Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy , 2011, Pigment Cell & Melanoma Research.

[31]  R. Landmann,et al.  Dysregulation of the host mevalonate pathway during early bacterial infection activates human TCR γδ cells , 2008, European journal of immunology.

[32]  A. Hayday,et al.  Identification of a Novel Proinflammatory Human Skin-Homing Vγ9Vδ2 T Cell Subset with a Potential Role in Psoriasis , 2011, The Journal of Immunology.

[33]  S. Rosenberg,et al.  MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte. , 1999, Cancer research.

[34]  K. Drzewiecki,et al.  Spontaneous regression of metastases from melanoma: review of the literature , 2009, Melanoma research.

[35]  R. Barnhill,et al.  Spontaneous regression of cutaneous tumors. , 1993, Advances in dermatology.

[36]  M. Atkins,et al.  High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. , 2000, The cancer journal from Scientific American.

[37]  C. Mackay,et al.  IL‐21 enhances the potential of human γδ T cells to provide B‐cell help , 2012, European journal of immunology.

[38]  P. Coulie,et al.  Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? , 2011, Cancer Immunology, Immunotherapy.

[39]  C. Lohse,et al.  Questionable Relevance of γδ T Lymphocytes in Renal Cell Carcinoma1 , 2008, The Journal of Immunology.

[40]  Yoshimasa Tanaka,et al.  Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study , 2007, Cancer Immunology, Immunotherapy.

[41]  A. Ribas Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). , 2008, The oncologist.

[42]  M. Todaro,et al.  Differentiation, phenotype, and function of interleukin-17-producing human Vγ9Vδ2 T cells. , 2011, Blood.

[43]  R. Warnke,et al.  Human lymphocytes bearing T cell receptor gamma/delta are phenotypically diverse and evenly distributed throughout the lymphoid system , 1989, The Journal of experimental medicine.

[44]  F. Poccia,et al.  CXCR5 Identifies a Subset of Vγ9Vδ2 T Cells which Secrete IL-4 and IL-10 and Help B Cells for Antibody Production1 , 2006, The Journal of Immunology.

[45]  Ceballos Pi,et al.  Spontaneous regression of cutaneous tumors. , 1993 .

[46]  S. Rosenberg,et al.  Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  R. Berger,et al.  Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies , 2008, Clinical Cancer Research.

[48]  M. Eberl,et al.  A Rapid Crosstalk of Human γδ T Cells and Monocytes Drives the Acute Inflammation in Bacterial Infections , 2009, PLoS pathogens.

[49]  G. De Libero,et al.  Human T Cell Receptor γδ Cells Recognize Endogenous Mevalonate Metabolites in Tumor Cells , 2003, The Journal of experimental medicine.

[50]  H. Pehamberger,et al.  Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  A. Mackensen,et al.  Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy , 2005, Cancer Immunology, Immunotherapy.

[52]  M. Eberl,et al.  Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. , 2007, Cancer research.

[53]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[54]  T. Sasada,et al.  Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance. , 2011, Immunotherapy.